

## Special Issue

# Communicable Diseases: New and Old Therapies and Preventive Strategies

### Message from the Guest Editors

The current era is characterized by emerging pathogens requiring continuous developments in both preventive and therapeutical strategies. Moreover, the risk of a resurgence of old pathogens necessitates new methods to tackle their spread, especially considering the alarming phenomenon of antimicrobial resistance. Additionally, the current era is also afflicted by reluctancy in vaccine acceptance, with "vaccine hesitancy" spreading throughout the world and leading to a reduction in vaccination coverage, despite vaccines' proven safety, efficacy and cost-effectiveness. In light of the above-mentioned public health challenges, we are pleased to invite you to contribute a paper to this Special Issue, which aims to provide articles on new preventive strategies and therapies and to discuss the challenges and the benefits seen with established ones.

---

### Guest Editors

Dr. Cristina Genovese

Dr. Calimeri Sebastiano

Dr. Daniela Lo Giudice

Dr. Vincenza La Fauci

Dr. Vincenza Gianfredi

---

### Deadline for manuscript submissions

closed (15 February 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/150500](https://mdpi.com/si/150500)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).